# DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

> **NCT03356080** · PHASE2 · UNKNOWN · sponsor: **Shanghai Tong Ren Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Cytarabine
- **DRUG:** All-transretinoic acid
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT03356080
- **Lead sponsor:** Shanghai Tong Ren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-07
- **Primary completion:** 2019-07-07
- **Final completion:** 2020-07-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356080, "DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03356080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*